Literature DB >> 21187868

Predictors of large volume paracantesis induced circulatory dysfunction in patients with massive hepatic ascites.

G Nasr1, A Hassan, S Ahmed, A Serwah.   

Abstract

PURPOSE: In patients with massive ascites, large volume paracentesis may be associated with complications as circulatory dysfunction. Selection of appropriate patients might reduce such side effects. PATIENTS AND METHODS: Forty-five patients known to have liver cirrhosis and presenting with massive ascites were included. There were 27 males and 18 females, with age (mean 51.2+10.64). All patients were subjected to full history, clinical examination, complete blood picture, prothrombin time, serum albumin, total plasma protein, serum bilirubin, serum creatinine, serum electrolytes and plasma renin activity measured by radioimmunoassay. Echocardiographic evaluation for cardiac output, pulmonary artery pressure, diastolic and systolic function before and after paracentesis. Large-volume paracentesis (LVP) ranging 8-18 liters with a mean 9.9 L was performed to all patients. Paracentesis induced circulatory dysfunction (PICD) was defined as increase in plasma renin activity (PRA) of more than 50% of pretreatment value to a level greater than 7.5ng /ml/ hour on the 6th day after paracentesis.
RESULTS: The incidence of PICD in patients with massive hepatic ascites was 73.3% (87.5% with Dextran and 38.5% with albumin). There were no serious systemic or local side effects one week following LVP. Type of plasma expander and younger ages were the only independent predictors (odd ratio OR with 95% confidence interval CI, 3.01<21.79<157.58 and 0.80<.88<.97 respectively) Gender and other clinical and laboratory parameters had no influence. Neither electrolytes levels nor hematocrite value had an influence. Ascitic patients showed higher heart rate and cardiac output and lower arterial pressure that was accentuated after LVP (P < 0.01). Echocardiographic diastolic function, A wave velocity and deceleration time of the E wave were markedly increased in cirrhotic patients with tense ascites and the E/A ratio was markedly reduced (0.9 ± 0.3) but was not significantly affected by LVP. Ejection fraction had similar values of the normal patients with a tendency to increase after paracentesis. There were no changes in the left ventricular wall thickness.
CONCLUSION: LVP is a safe and effective procedure for treatment of tense/refractory ascites. PICD is a frequently occurring silent complication following LVP. Salt free human albumin should be the plasma expander of choice especially if at least 8 liters are evacuated. Left ventricular diastolic function is altered in cirrhosis with tense ascites. This may represent an early stage of hepatic cardiomyopathy but was not affected by LVP and this was not reflected on the occurrence of PICD.

Entities:  

Keywords:  Circulatory dysfunction; hepatic cardiomyopathy; massive hepatic ascites

Year:  2010        PMID: 21187868      PMCID: PMC2982202          DOI: 10.4103/0975-3583.70914

Source DB:  PubMed          Journal:  J Cardiovasc Dis Res        ISSN: 0975-3583


  50 in total

Review 1.  Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management.

Authors:  Vicente Arroyo; Jordi Colmenero
Journal:  J Hepatol       Date:  2003       Impact factor: 25.083

Review 2.  The sympathetic nervous system in liver disease.

Authors:  J H Henriksen; S Møller; H Ring-Larsen; N J Christensen
Journal:  J Hepatol       Date:  1998-08       Impact factor: 25.083

3.  Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt.

Authors:  M Huonker; Y O Schumacher; A Ochs; S Sorichter; J Keul; M Rössle
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

4.  The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites.

Authors:  A Ochs; M Rössle; K Haag; K H Hauenstein; P Deibert; V Siegerstetter; M Huonker; M Langer; H E Blum
Journal:  N Engl J Med       Date:  1995-05-04       Impact factor: 91.245

5.  Euvolemic cirrhotic dogs in sodium balance maintain normal systemic hemodynamics.

Authors:  M Levy; E Maher; M J Wexler
Journal:  Can J Physiol Pharmacol       Date:  1988-01       Impact factor: 2.273

6.  Mechanisms of early decrease in systemic vascular resistance after total paracentesis: influence of flow rate of ascites extraction.

Authors:  Susanna Coll; Maria Carme Vila; Lluis Molina; Maria Dolores Gimenez; Carlos Guarner; Ricard Solà
Journal:  Eur J Gastroenterol Hepatol       Date:  2004-03       Impact factor: 2.566

7.  Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study.

Authors:  P Ginés; V Arroyo; E Quintero; R Planas; F Bory; J Cabrera; A Rimola; J Viver; J Camps; W Jiménez
Journal:  Gastroenterology       Date:  1987-08       Impact factor: 22.682

8.  Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study.

Authors:  Virendra Singh; Ramesh Kumar; Chander Kanwal Nain; Baljinder Singh; Arun K Sharma
Journal:  J Gastroenterol Hepatol       Date:  2006-01       Impact factor: 4.029

9.  Total paracentesis with dextran 40 vs diuretics in the treatment of ascites in cirrhosis: a randomized controlled study.

Authors:  R Solà; M C Vila; M Andreu; M I Oliver; S Coll; J Gana; S Ledesma; P Ginès; W Jiménez; V Arroyo
Journal:  J Hepatol       Date:  1994-02       Impact factor: 25.083

10.  Paracentesis of ascitic fluid. A safe procedure.

Authors:  B A Runyon
Journal:  Arch Intern Med       Date:  1986-11
View more
  14 in total

Review 1.  Kidneys in chronic liver diseases.

Authors:  Marek Hartleb; Krzysztof Gutkowski
Journal:  World J Gastroenterol       Date:  2012-06-28       Impact factor: 5.742

2.  Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study.

Authors:  Hiang Keat Tan; Paul Damien James; Florence Wong
Journal:  Dig Dis Sci       Date:  2016-04-05       Impact factor: 3.199

Review 3.  Diastolic dysfunction in cirrhosis.

Authors:  Søren Møller; Signe Wiese; Hanne Halgreen; Jens D Hove
Journal:  Heart Fail Rev       Date:  2016-09       Impact factor: 4.214

4.  Management of renal failure and ascites in patients with cirrhosis.

Authors:  Kaushal Madan; Ashish Mehta
Journal:  Int J Hepatol       Date:  2011-09-27

5.  Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis.

Authors:  Rosa G Simonetti; Giovanni Perricone; Dimitrinka Nikolova; Goran Bjelakovic; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2019-06-28

Review 6.  Management of refractory ascites in cirrhosis: Are we out of date?

Authors:  Alagappan Annamalai; Lauren Wisdom; Megan Herada; Mazen Nourredin; Walid Ayoub; Vinay Sundaram; Andrew Klein; Nicholas Nissen
Journal:  World J Hepatol       Date:  2016-10-08

7.  Cirrhotic Patients on Mechanical Ventilation Have a Low Rate of Successful Extubation and Survival.

Authors:  Roula Sasso; Steven Lauzon; Don C Rockey
Journal:  Dig Dis Sci       Date:  2020-01-20       Impact factor: 3.199

8.  Effects of paracentesis on hemodynamic parameters and respiratory function in critically ill patients.

Authors:  Veit Phillip; Bernd Saugel; Christina Ernesti; Alexander Hapfelmeier; Caroline Schultheiß; Philipp Thies; Ulrich Mayr; Roland M Schmid; Wolfgang Huber
Journal:  BMC Gastroenterol       Date:  2014-01-27       Impact factor: 3.067

9.  The impact of paracentesis flow rate in patients with liver cirrhosis on the development of paracentesis induced circulatory dysfunction.

Authors:  Maha Mohammad Elsabaawy; Shimaa Rashad Abdelhamid; Ayman Alsebaey; Eman Abdelsamee; Manar Abdelaal Obada; Tary Abdelhamid Salman; Eman Rewisha
Journal:  Clin Mol Hepatol       Date:  2015-12-24

10.  Hemodynamic Evaluation of Nonselective β-Blockers in Patients with Cirrhosis and Refractory Ascites.

Authors:  Alberto Ferrarese; Valerie Tikhonoff; Edoardo Casiglia; Paolo Angeli; Silvano Fasolato; Diego Faggian; Alberto Zanetto; Giacomo Germani; Francesco Paolo Russo; Patrizia Burra; Marco Senzolo
Journal:  Gastroenterol Res Pract       Date:  2018-05-09       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.